Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial

被引：0

作者：

Matthias, Griese ^{[1
]}

Robin, Deterding ^{[2
,3
]}

Lisa, Young R. ^{[4
]}

Emily, DeBoer M. ^{[2
,3
]}

David, Warburton ^{[5
,6
]}

Steven, Cunningham ^{[7
]}

Nicolaus, Schwerk ^{[8
]}

Kevin, Flaherty R. ^{[9
]}

Kevin, Brown K. ^{[10
]}

Mihaela, Dumistracel ^{[11
]}

Elvira, Erhardt ^{[12
]}

Julia, Bertulis ^{[12
]}

Martina, Gahlemann ^{[13
]}

Susanne, Stowasser ^{[14
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Hauner Childrens Hosp, German Ctr Lung Res DZL, Munich, Germany

[2] Univ Colorado Denver, Sect Pediat Pulm & Sleep Med, Dept Pediat, Denver, CO USA

[3] Childrens Hosp Colorado, Aurora, CO USA

[4] Childrens Hosp Philadelphia, Div Pulm & Sleep Med, Philadelphia, PA USA

[5] Childrens Hosp Los Angeles, Los Angeles, CA USA

[6] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA

[7] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland

[8] Hannover Med Sch, Clin Pediat Pulmonol Allergol & Neonatol, Hannover, Germany

[9] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA

[10] Natl Jewish Hlth, Dept Med, Denver, CO USA

[11] Boehringer Ingelheim Pharma GmbH Co KG, Ingelheim, Germany

[12] Boehringer Ingelheim Pharma GmbH Co KG, Biberach, Germany

[13] Boehringer Ingelheim Schweiz GmbH, Basel, Switzerland

[14] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

来源：

KLINISCHE PADIATRIE | 2023年 / 235卷 / 02期

关键词：

D O I：

10.1055/s-0043-1761556

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

P46

引用

页码：125 / 125

页数：1

共 50 条

[31] Nintedanib in Progressive Fibrosing Interstitial Lung Disease (PFILD): Assessing Renal Function Trends and Tolerability
Johnston, Janet
Newman, Kate
Montgomery, Holly
Garfoot, Theresa
Hayton, Conal
Rivera-Ortega, Pilar
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[32] Photosensitive dermatitis caused by nintedanib in a patient of chronic fibrosing interstitial lung disease already on pirfenidone
Goyal, Aurelia
Gupta, Sharang
Chopra, Dimple
INDIAN JOURNAL OF PHARMACOLOGY, 2024, 56 (05) : 367 - 368
[33] Outcomes in real-life nintedanib treatment of progressive fibrosing interstitial lung disease.
Calzolari, Elisa
Callari, Adriana
Martino, Lavinia
Lanzarone, Nicola
Miceli, Vitale
Vitulo, Patrizio
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[34] EFFECTS OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS (RA-ILD) IN THE INBUILD TRIAL
Kelly, C.
Matteson, E.
Aringer, M.
Burmester, G. R.
Mueller, H.
Moros, L.
Rohr, K.
Kolb, M.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 69 - 69
[35] Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the INBUILD trial
Koschel, D.
Kelly, C.
Matteson, E.
Aringer, M.
Burmester, G.
Mueller, H.
Moros, L.
Rohr, B. K.
Kolb, M.
PNEUMOLOGIE, 2022, 76 : S21 - S21
[36] Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib
Makino, Shigeki
MODERN RHEUMATOLOGY, 2021, 31 (01) : 13 - 19
[37] From Bench to Bedside: Nintedanib for Progressive Fibrosing Interstitial Lung Diseases
Garlick, Kristopher
Wollin, Lutz
Distler, Joerg
Stowasser, Susanne
Schlenker-Herceg, Rozsa
JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 822 - 822
[38] Nintedanib in chronic fibrosing interstitial lung diseases. A case series
Sevila, Raquel Garcia
Jimenez, Juan Jose Arenas
Casasempere, Paloma Vela
Perez, Ester Nofuentes
Garcia-Manso, Ignacio Gaya
HELIYON, 2024, 10 (07)
[39] FROM BENCH TO BEDSIDE: NINTEDANIB FOR PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES
Wollin, L.
Distler, J.
Redente, E.
Riches, D.
Stowasser, S.
Schlenker-Herceg, R.
RESPIROLOGY, 2019, 24 : 171 - 171
[40] Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analyses from the INBUILD Trial
Kolb, M. R.
Flaherty, K. R.
Silva, R. S.
Prasse, A.
Patel, N. M.
Vancheri, C.
Quaresma, M.
Goeldner, R.
Stowasser, S.
Schlenker-Herceg, R.
Wells, A. U.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201

← 1 2 3 4 5 →